Induced pluripotent stem cell (iPSC)-derived therapies are emerging as a next-generation allogeneic platform due to their ability to differentiate into diverse somatic cell types. The quality of the starting cell bank is critical to therapeutic success, making efficient and reproducible vial filling an essential step in manufacturing.
Manual vial filling remains the industry standard despite challenges around scalability, vial-to-vial and bank-to-bank variability, sterility risks, processing times and demands on operators and cleanroom resources.
This application note highlights evaluative research of Celleo’s Larkem® V40 automated, closed fill system in comparison with traditional manual pipetting. Key analysis includes process efficiency, vial fill accuracy, output cell viability, concentration, iPSC pluripotency, post-thaw recovery, and reproducibility. Research was undertaken at the Cell and Gene Therapy Catapult (CGT Catapult) Edinburgh laboratories.
Download the application note.
About Celleo
Celleo delivers intelligent production systems that enable efficient, scalable cell and gene therapy manufacture, with the vision of advancing transformative therapies toward population-level health impact. Celleo systems support leading biopharmaceuticals, CDMOs and developers of novel therapeutics across key workflows, including cell banking, drug product, QC samples, critical reagent preparation, and other emerging applications. To learn more, visit celleo.com
